The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

This Master’s degree is open to applicants with a first-degree or a higher degree, making use of the Nursing & Midwifery Council’s (NMC) provision for prior learning to achieve professional ...

To make up for looming revenue gaps, Roop said Big Pharma will increasingly turn to M&A next year, buying smaller biotechs developing drugs in major markets such as obesity and oncology.

Health Secretary Wes Streeting said the plans announced today “will help to modernise social care, get it working more closely with the NHS, and help deliver our Plan for Change.” He said ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

The anti-obesity drug Zepbound made by Eli Lilly ... The list price of Zepbound is $1,086.37 per fill, according to a pricing plan Lilly announced last year but the amount someone pays depends ...

recently endorsed their use to combat the obesity epidemic. Experts, however, caution that these drugs must be paired with a balanced diet and regular exercise, as part of a comprehensive care ...